Pharmaxis Ltd’s (ASX:PXS) Gary Phillips says first results from a three-stage phase 1c clinical trial (MF-101) studying a potential treatment for bone marrow cancer myelofibrosis, have demonstrated strong inhibition of target enzymes LOX and LOXL2 in patients. The study aims to demonstrate that PXS-5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Pharmaxis encouraged by first results in bone marrow cancer trial
Quick facts: Pharmaxis Ltd
Price: 0.1275 AUD
Market Cap: $57.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE